Today's Date: June 6, 2023
Antibiotic Overuse a Slippery Slope for STI Prevention, says AHF   •   RK Pharma to receive up to USD 200 million investment from PAG   •   ACC Honors Companies for Efforts to Advance Sustainability with its 2023 Sustainability Leadership Awards   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of SentinelOne, Inc.   •   Morgan Stanley Global M&A Chair Robert Kindler to Join Paul, Weiss   •   Lost Money in Tingo Group, Inc.?   •   Coalition For Change (C4C) Releases Report to President Biden on EEOC's Flawed EEO Complaint System   •   S CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SentinelOne, Inc.   •   PRIMO Partners Honored with Distinguished 2023 MVP Award from Multi-Unit Franchisee Magazine   •   WCM Champions of Change Close the Market   •   Coach Nick Saban, Ms. Terry Saban surprise children with award-winning My Special Aflac Duck®   •   With New Recycling Center Fully Operational, EGGER Now Manufactures Products With Post-Consumer Recycled Wood   •   Maine Public Utilities Commission Unanimously Approve Central Maine Power Multi-year Rate Plan   •   Roth Staffing Named to ClearlyRated's Inaugural Best Staffing Firms for Women List   •   AVOCADO TO DONATE 1% OF REVENUE TO WOMEN'S EARTH ALLIANCE   •   PrideStaff Financial Named to ClearlyRated's Best Staffing Firms for Women List   •   University of Phoenix Collaborates with Ardent Health Services to Provide Education and Tuition Reimbursement for Employees   •   PrideStaff Named to ClearlyRated's Best Staffing Firms for Women List   •   Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Funko, Inc. (FNKO)   •   Devonian Announces Closing of a Private Placement of $1.2 Million
Bookmark and Share

Presidio Medical™ Announces Executive Appointment

SOUTH SAN FRANCISCO, Calif. , March 21 /Businesswire/ - Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer. Mr. Salys is a 25-year veteran in Class III active implantable devices leading R&D, Operations, Supply Chain, Program Management, and Durable Medical Equipment (DME) organizations. Mr. Salys joins Presidio from Abbott where he was most recently the Divisional Vice President of R&D of the Heart Failure business.

“We are thrilled to have someone with Scott’s breadth of experience across Operations, Supply Chain, and R&D join the Presidio team. Not only does Scott have functional expertise in key areas for Presidio’s progression, but he has managed several business lines within cardiac rhythm management and neuromodulation, which is complimentary to the platform Presidio is building,” said Michael Onuscheck, Chairman and CEO of Presidio Medical.

“I am excited to join this incredibly talented team and lead Presidio Medical through the next stage of clinical and product development. We have the unique opportunity to create neuromodulation therapies for new patient populations as well as transform conventional neuromodulation therapy. I am passionate about building high-performing teams and look forward to delivering our novel ULF platform to patients,” said Mr. Salys.

Prior to joining Presidio Medical, Mr. Salys was the Divisional Vice President of R&D (2021 to 2022) and Divisional Vice President of Operations (2017 to 2021) in Abbott’s Heart Failure business, where he led the organization through a phase of rapid growth and expansion. In addition to roles in R&D and Operations, Mr. Salys transformed the Heart Failure DME business by shifting strategy, building the team, and establishing a commercial organization that delivered triple digit growth. Mr. Salys also served on Abbott’s Executive Crisis Management Team, Scientific Governing Board, as well as the Board of Directors for Abbott Global Enterprises.

Prior to Abbott’s acquisition of St. Jude Medical (SJM) in 2017, Mr. Salys spent over 16 years at SJM in R&D, Operations, and Supply Chain roles across various divisions and geographies. Scott’s most recent roles at SJM included Vice President of Operations and R&D, VP of Supply Chain, VP of Operations, and VP of Program Management. Mr. Salys successfully integrated newly acquired businesses, strengthened global organizations, executed change management initiatives, and delivered rapid growth in the neuromodulation and cardiac resynchronization therapy markets.


Presidio Medical was founded in 2017 and is headquartered in South San Francisco, CA. The clinical-stage, privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity with a first indication in the treatment of chronic pain. Presidio’s current investors include Invus Opportunities and Action Potential Venture Capital. For more information, visit

STORY TAGS: California, Science, Cardiology, Other Science, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, Personnel, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News